Strongyloidiasis medical therapy

Revision as of 13:19, 21 June 2017 by Aditya Ganti (talk | contribs)
Jump to navigation Jump to search

Strongyloidiasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Strongyloidiasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Strongyloidiasis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Strongyloidiasis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Strongyloidiasis medical therapy

CDC on Strongyloidiasis medical therapy

Strongyloidiasis medical therapy in the news

Blogs on Strongyloidiasis medical therapy

Directions to Hospitals Treating Strongyloidiasis

Risk calculators and risk factors for Strongyloidiasis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

The drug of choice for the treatment of uncomplicated strongyloidiasis is ivermectin with albendazole as the alternative. All patients who are at risk of disseminated strongyloidiasis should be treated.[1]

Treatment

Antimicrobial Regimen

  • Strongyloides stercoralis
  • Preferred regimen: Ivermectin 200 mcg/kg/day PO qd for 2 days or two doses 2 weeks apart from each other[2]
  • Alternative regimen: Albendazole 400 mg PO bid for 3-7 days[3]

References

  1. http://www.dpd.cdc.gov/dpdx/HTML/Strongyloidiasis.htm
  2. "WGO Practice Guideline Management of Strongyloidiasis" (PDF).
  3. Archibald LK, Beeching NJ, Gill GV, Bailey JW, Bell DR (1993). "Albendazole is effective treatment for chronic strongyloidiasis". Q J Med. 86 (3): 191–5. PMID 8483992.

Template:WH Template:WS